Healthcare in Oman
Regulatory submission platform failures in Oman pharmaceutical companies typically share one root cause: the validation consulting firm produced a gap report instead of a compliant system. FDA 21 CFR Part 11 audit trail requirements were not designed in. The UAE PDPL and DIFC compliance posture requires architectural rebuild, not documentation remediation.
Pharmaceutical technology lives under FDA 21 CFR Part 11. Data integrity isn't optional — it's existential. Clinical trial data, manufacturing execution, regulatory submissions — every system requires validated, compliant infrastructure.
How We Deliver in Oman
UAE & Gulf and Healthcare Frameworks
Healthcare organizations in Oman operate under both UAE & Gulf regional frameworks and sector-specific compliance requirements. We embed all applicable frameworks architecturally — not as a parallel compliance workstream running alongside engineering.